Cash-Pay Longevity Clinics in 2026: Evidence and Conflict-of-Interest Questions
Cash payment is not itself a warning sign, but selling tests or products can create conflicts. Use this evidence contract to separate the medical fee, product revenue, claims, and follow-up.
Review note, August 28, 2026: The original GlobalRPH article was not accessible during this audit. WLC therefore replaced unsupported claims about accreditation, registries, and future guidelines with an independently checkable framework based on the AMA Code of Medical Ethics and FDA compounding guidance.
A cash-pay medical model can fund longer consultations, coordinated testing, and follow-up that insurance may not cover. It can also create a conflict when the same clinic recommends and sells the test, supplement, infusion, or compounded medicine.
The payment method is not the verdict. The useful question is whether the clinic can produce an evidence and conflict-of-interest contract for each recommendation.
What professional ethics require when a physician sells products
The American Medical Association Code of Medical Ethics says physician sales of health-related products can create financial conflicts, place undue pressure on patients, and undermine trust.
Its opinion gives concrete safeguards. Physicians should:
- limit sales to products with scientifically valid claims and reliable evidence;
- explain risks, benefits, and limits in language the patient can understand;
- disclose their financial interest;
- tell patients whether equivalent products are available elsewhere;
- avoid exclusive arrangements that restrict choice unless those arrangements protect product quality or patient safety.
This guidance focuses on product sales, not every membership or professional fee. It is still a useful standard wherever a clinic earns more when a patient accepts an add-on.
Build the evidence contract before paying
| Line item | What the clinic should disclose | Warning sign |
|---|---|---|
| Professional fee | Clinician time, records reviewed, decisions delivered, and follow-up included | A large fee is described only as access to “optimization” |
| Diagnostic test | Clinical question, laboratory or imaging provider, decision threshold, and incidental-finding pathway | The number of biomarkers substitutes for a medical rationale |
| Product or drug | Exact name, manufacturer or pharmacy, approval or compounding status, indication, dose, and alternatives | The clinic sells a category such as “peptides” without identifying the product |
| Evidence | Human population, comparator, outcome, duration, and important harms | Mechanism, testimonial, or biomarker change is presented as proven healthspan benefit |
| Financial interest | Margin, referral payment, ownership, or exclusive supplier relationship where applicable | The prescriber says conflicts are irrelevant because the patient pays voluntarily |
| Follow-up | Named clinician, monitoring interval, stop criteria, adverse-event route, and referral responsibility | Payment ends after a report or treatment is delivered |
This document can be one page. Its value comes from connecting each payment to a clinical decision and an accountable person.
Compounded medicine needs an additional disclosure
The FDA compounding Q&A states that compounded drugs are not FDA-approved. FDA does not verify their safety, effectiveness, or quality before marketing.
Compounding can meet a legitimate patient need when an approved medicine is unsuitable in its available form. It should not be presented as a more personalized version of approval.
For a compounded product, ask:
- Why does an FDA-approved product not meet this patient’s medical need?
- Is the medicine prepared under section 503A or by a registered 503B outsourcing facility?
- Which pharmacy made it, and what are the formulation, lot, storage, and beyond-use details?
- What evidence supports this ingredient, dose, route, and indication?
- Who monitors adverse effects and reports quality problems?
The regulatory pathway does not by itself prove that treatment is appropriate. It lets the buyer identify who made the medicine and which safeguards apply.
How to detect a recommendation distorted by the business model
Three comparisons are especially revealing.
With and without the add-on. Ask the clinician to describe the plan if the clinic did not sell the recommended product. The medical rationale should survive that hypothetical.
Clinic price and outside price. If an equivalent product or test can be obtained elsewhere, the patient should be able to compare it without losing access to care.
Standard care and experimental care. Guideline-based risk reduction, an off-label prescription, a compounded product, and an investigational intervention should not appear as equivalent menu items.
Cash payment also makes outcome accountability more important. A clinic that charges directly can specify which outcomes it tracks, how it handles abnormal results, and when it stops an ineffective intervention. Use the WLC outcomes scorecard to evaluate that layer.
A defensible cash-pay model
A serious clinic does not need to claim that every service extends life. It needs to show:
- what the patient is buying;
- which part is professional judgment and which part is a product sale;
- what evidence supports the intended outcome;
- which uncertainties and financial interests exist;
- and who remains responsible after payment.
That transparency does more to distinguish evidence-based care from commercial experimentation than a certificate, premium facility, or proprietary protocol.
Main source: AMA Code of Medical Ethics, Opinion 9.6.4, Sale of Health-Related Products, reviewed August 28, 2026. Additional regulatory context: FDA Compounding and FDA Q&A.